We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Adiponectin Linked to Cancer Risk in Diabetes

By LabMedica International staff writers
Posted on 17 Mar 2020
Print article
Image: A Total Adiponectin ELISA Assay Kit: higher serum adiponectin concentration has been independently associated with incident cancer and cancer-related deaths in type 2 diabetes (Photo courtesy of Mediagnost).
Image: A Total Adiponectin ELISA Assay Kit: higher serum adiponectin concentration has been independently associated with incident cancer and cancer-related deaths in type 2 diabetes (Photo courtesy of Mediagnost).
Adiponectin is a protein hormone that modulates a number of metabolic processes, including glucose regulation and fatty acid oxidation. Adiponectin is secreted from adipose tissue, and also from the placenta in pregnancy, into the bloodstream and is very abundant in plasma relative to many hormones.

Despite the beneficial cardiometabolic effects of adiponectin demonstrated in preclinical studies, paradoxically higher circulating adiponectin concentrations have been found in epidemiological studies to be associated with incident cardiovascular events, renal outcomes, and mortality in patients with diabetes.

Medical scientists at the University of Hong Kong (Pokfulam, Hong Kong, China) and their colleagues carried out a prospective cohort study, and analyzed data from 5,658 adults with type 2 diabetes recruited from the Hong Kong West Diabetes Registry (median follow-up, 6.5 years). The team measured baseline serum adiponectin concentrations and stratified participants according to adiponectin tertiles (< 7.23 µg/mL, 7.23-12 µg/mL, >12 µg/mL), and used Cox regression analysis to estimate associations between circulating adiponectin concentrations with incident cancer and cancer-related mortality.

The investigators reported that over a median-follow up of 6.5 years, 7.53% and 3% of participants developed cancer and had cancer-related deaths, respectively. Serum adiponectin concentrations were significantly higher in those who had incident cancer (9.8 μg/mL versus 9.1 μg/mL) and cancer-related deaths (11.5 μg/mL versus 9.3 μg/mL) compared with those without. Moreover, in multivariable analyses, serum adiponectin concentration was independently associated with both incident cancer (hazard ratio (HR) = 1.19) and cancer-related deaths (HR = 1.23). In sex-stratified analyses, the association between serum adiponectin and incident cancer was only observed among men (HR = 1.23).

The authors concluded that higher serum adiponectin concentration was independently associated with incident cancer and cancer-related deaths in type 2 diabetes, indicating that adiponectin paradox can be observed in another major diabetic complication in addition to cardiovascular and kidney diseases.

Karen Lam, MD, professor of medicine and the senior author of the study, said, “Although adiponectin, a hormone from the fat cells, has been reported to protect against cancers in animal studies, mostly in mice, higher levels of adiponectin paradoxically predicted the development of cancer and death due to cancers in this study of more than 5,000 people with diabetes”. The study was published online on February 19, 2020 in The Journal of Clinical Endocrinology & Metabolism.

Related Links:
University of Hong Kong

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.